The primary objective of this study is to establish scores of Cognitive impairment (CI) of the 3 DigiCog [Brief Computerized Cognitive Assessment for Multiple Sclerosis (BCCAMS) app] tests [Computerized Speed Cognitive Test (CSCT), Computerized Episodic Visual Memory Test (CEVMT) and the French Learning Test (FLT), a verbal memory test similar to the CVLT], using a tablet application in a sample of healthy participants matched to persons with MS (PwMS).

The secondary objectives of this study are to determine the ability of the DigiCog app to detect cognitive impairment (CI) compared to the classical Brief International Cognitive Assessment for MS (BICAMS) in PwMS; to determine the relationship between depressive symptoms and cognitive performance in Multiple Sclerosis (MS) sample; to determine the relationship between subjective perception of CI and cognitive performance ; to evaluate the reliability of Konectom™ digital outcome assessments (DOAs) in healthy subjects (HS) and PwMS; to evaluate the convergent validity of Konectom™ digital outcome assessments (DOAs) against in-clinic conventional disability outcome assessments in PwMS; to evaluate differences in Konectom™ DOAs [self administered at home and in-clinic] between PwMS and HS; to evaluate the variability of Konectom™ DOAs self-administered at home in free-living environment in HS and PwMS; to compare Konectom™ DOAs between in-clinic supervised administration versus self-assessments in free-living environment in HS and PwMS; to evaluate the clinical meaningfulness of Konectom™ DOAs against Patient-Reported Outcomes (PRO) in PwMS.

Inclusion Criteria:

For PwMS:

• Expanded Disability Status Scale (EDSS) score ≤ 6.
• Multiple Sclerosis (MS) diagnosis according to 2017 revised McDonald criteria.

For Healthy Participants:

- Gender-, age- and education-matched with Multiple Sclerosis participants.

Exclusion Criteria:

For PwMS:

• Severe depression according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) classification or severe on-going psychiatric condition, as per evaluation by the investigator;
• Change of Disease Modifiying Treatment (DMT) in the last 1 month;
• Any clinically significant neurological disorders other than MS, as per evaluation by the investigator;
• Any change of psychotropic treatment in the last 1 month;
• Clinically significant addiction (alcohol or other drug abuse), as per evaluation by the investigator;
• Recent acute relapse or disability worsening (less than one month);
• Steroid course in the previous month;
• Neuropsychological testing with the following tests in the previous year: Full BICAMS or DigiCog (BCCAMS app) battery, Fatigue Scale for Motor and Congnitive functions (FSMC), Computerized speed cognitive test (CSCT), Computerized Episodic Visual Memory Test (CEVMT), French Learning Test (FLT), Cognitive processing speed (CPS), Symbol Digit Modalities Test (SDMT);
• Developmental learning disabilities, as per evaluation by the investigator;
• Pregnant or breastfeeding women

For Health Participants:

• Severe depression (according to DSM-5 classification) or severe on-going psychiatric condition, as per evaluation by the investigator;
• Any clinically significant neurological disorders, as per evaluation by the investigator;
• Any psychotropic therapy consumption;
• Clinically significant addiction (alcohol or other drug abuse), as per evaluation by the investigator;
• Clinically significant cognitive complaint(s), as per evaluation by the investigator;
• Previous participation in other cognitive study using the same tests (Full BICAMS or DigiCog (BCCAMS app) battery, Fatigue Scale for Motor and Congnitive functions (FSMC), Computerized speed cognitive test (CSCT), Computerized Episodic Visual Memory Test (CEVMT), French Learning Test (FLT), Cognitive processing speed (CPS), Symbol Digit Modalities Test (SDMT));
• Developmental learning disabilities, as per evaluation by the investigator;
• Pregnant or breastfeeding women.

NOTE: Other protocol defined inclusion/ exclusion criteria may apply.

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/